Literature DB >> 15838671

[Novel guidelines for antihypertensive treatment. Proven and new].

W Zidek1.   

Abstract

Arterial hypertension is the most common internal disorder. Therefore, rational strategies in diagnostic and therapeutic procedures are especially important. In the diagnosis of hypertension, basic and special diagnostic procedures are established, the former being restricted to few procedures. Basic diagnostic procedures should be applied to any patient with hypertension. Special diagnostic procedures should only be applied if basic procedures show abnormalities, if patients are resistant to conventional treatment or show any other signs suggestive of secondary hypertension. The basis of drug treatment consists of the following first line antihypertensive drugs: diuretics, beta blockers, calcium channel blockers, ACE inhibitors, and AT1 blockers. Differential therapy is based on the condition of the individual patient. Rational treatment strategies include stepped care, initial low-dose combination therapy, and sequential monotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15838671     DOI: 10.1007/s00108-005-1410-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  6 in total

1.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

2.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

3.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

4.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

5.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

6.  Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension.

Authors:  J A Staessen; L Thijs; R H Fagard; W H Birkenhäger; G Arabidze; S Babeanu; B Gil-Extremera; C J Bulpitt; C Davidson; P W de Leeuw; A D Efstratopoulos; A E Fletcher; R Fogari; M Jääskivi; K Kawecka-Jaszcz; C Nachev; J C Petrie; M L Seux; J Tuomilehto; J Webster; Y Yodfat
Journal:  Hypertension       Date:  1998-09       Impact factor: 10.190

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.